Incidence of type 2 diabetes, cardiovascular disease and chronic kidney disease in patients with multiple sclerosis initiating disease-modifying therapies: Retrospective cohort study using a frequentist model averaging statistical framework
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0300708 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift PLOS ONE, 2024. Verfasst von Alan J M Brnabic und 8 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, United States of America. Hauptthemen laut MEDLINE: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Cardiovascular Diseases, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eli Lilly and Company.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Researchers are increasingly using insights derived from large-scale, electronic healthcare data to inform drug development and provide human validation of novel treatment pathways and aid in drug repurposing/repositioning. The objective of this study was to determine whether treatment of patients with multiple sclerosis with dimethyl fumarate, an activator of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, results in a change in incidence of type 2 diabetes and its complications. This retrospective cohort study used administrative claims data to derive four cohorts of adults with multiple sclerosis initiating dimethyl fumarate, teriflunomide, glatiramer acetate or fingolimod between January 2013 and December 2018. A causal inference frequentist model averaging framework based on machine learning was used to compare the time to first occurrence of a composite endpoint of type 2 diabetes, cardiovascular disease or chronic kidney disease, as well as each individual outcome, across the four treatment cohorts. There was a statistically significantly lower risk of incidence for dimethyl fumarate versus teriflunomide for the composite endpoint (restricted hazard ratio [95% confidence interval] 0.70 [0.55, 0.90]) and type 2 diabetes (0.65 [0.49, 0.98]), myocardial infarction (0.59 [0.35, 0.97]) and chronic kidney disease (0.52 [0.28, 0.86]). No differences for other individual outcomes or for dimethyl fumarate versus the other two cohorts were observed. This study effectively demonstrated the use of an innovative statistical methodology to test a clinical hypothesis using real-world data to perform early target validation for drug discovery. Although there was a trend among patients treated with dimethyl fumarate towards a decreased incidence of type 2 diabetes, cardiovascular disease and chronic kidney disease relative to other disease-modifying therapies–which was statistically significant for the comparison with teriflunomide–this study did not definitively support the hypothesis that Nrf2 activation provided additional metabolic disease benefit in patients with multiple sclerosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, United States of America.
ORCID-Profile: Alan J M Brnabic, Joseph A Johnston
Förderung
- Eli Lilly and Company
Zitieren
APA
Brnabic, A. J. M., Curtis, S. E., Johnston, J. A., Lo, A., Zagar, A. J., Lipkovich, I., Kadziola, Z., Murray, M. H., & Ryan, T. (2024). Incidence of type 2 diabetes, cardiovascular disease and chronic kidney disease in patients with multiple sclerosis initiating disease-modifying therapies: Retrospective cohort study using a frequentist model averaging statistical framework. PLOS ONE. https://doi.org/10.1371/journal.pone.0300708
Vancouver
Brnabic AJM, Curtis SE, Johnston JA, Lo A, Zagar AJ, Lipkovich I, et al. Incidence of type 2 diabetes, cardiovascular disease and chronic kidney disease in patients with multiple sclerosis initiating disease-modifying therapies: Retrospective cohort study using a frequentist model averaging statistical framework. PLOS ONE. 2024. doi:10.1371/journal.pone.0300708
BibTeX
@article{Brnabic2024,
author = {Brnabic, Alan J M and Curtis, Sarah E and Johnston, Joseph A and Lo, Albert and Zagar, Anthony J and Lipkovich, Ilya and Kadziola, Zbigniew and Murray, Megan H and Ryan, Timothy},
title = {Incidence of type 2 diabetes, cardiovascular disease and chronic kidney disease in patients with multiple sclerosis initiating disease-modifying therapies: Retrospective cohort study using a frequentist model averaging statistical framework},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0300708}
}
EUVIMED